Past Champ Nasdaq Biotech (GNPX) Has 4 Potential Driver Indicators Including Positive Preclinical Data

StockWireNews

Past Champ Nasdaq Biotech (GNPX) Has 4 Potential Driver Indicators Including Positive Preclinical Data

National Securities Provides $7.00 Price Target (MarketBeat)

May 4th

Good Morning,

There's no time to waste this morning as your past champ NASDAQ biotech profile Genprex, Inc. (GNPX) could be breakout bound.

I've brought this profile to you on several occasions over the past couple years only to watch it go on major runs.

Back on 2/11/20, GNPX was alerted at approximately $1.61 and ran to a 2/25/20 high of $7.03 for an approximate 336% move.

I followed up with GNPX when I brought it to your attention on 7/22/20 and watched it run from an open of $3.45 to 7/23/20's high of $4.50 for a two day surge of approximately 30%.

Finally, I brought it back on 12/22/20 when it opened at $4.10 before reaching a $7.72 high on February 8th of this year for an approximately 88% move.

Genprex, Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.

GNPX's MAJOR COMPETITIVE ADVANTAGES

(From The Company Presentation)

GENE THERAPY PLATFORM. Our non-viral Oncoprex® nanoparticle delivery system is designed to deliver a variety of therapeutic genes to fight cancer. Data indicate that our lead drug candidate, REQORSA™ immunogene therapy, may be combined with a number of approved cancer drugs, and that it may be effective against many types of cancer, including non-small cell lung cancer, glioblastoma, head and neck cancer, breast cancer (including triple negative breast cancer), renal cell carcinoma, and soft tissue carcinoma.

FIRST IN HUMANS. We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy to be used for cancer in humans.

LARGE MARKETS AND UNMET NEED IN CANCER & DIABETES. Our initial disease indication is non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer deaths worldwide. NSCLC constitutes approximately 84% of lung cancers, and the projected market size of lung cancer therapeutics is expected to grow to $26.3Bn by 2023. We are also developing a separate therapy for diabetes, with a projected $78.2Bn market by the end of 2026.

REQORSA™ CAN BE COMBINED WITH AND MAY IMPROVE THE BENEFITS OF TOP-SELLING CANCER DRUGS. REQORSA is synergistic with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including Tagrisso, and with checkpoint inhibitors, including Keytruda. Tagrisso, with sales of more than $3Bn in 2019, is AstraZeneca’s largest selling drug. Keytruda, with sales of more than $11Bn in 2019, is Merck’s largest selling drug. Data show that combining REQORSA with Tagrisso or Keytruda achieves more favorable results than either drug alone.

FDA FAST TRACK DESIGNATION for use of REQORSA, combined with Astra Zeneca’s Tagrisso, in late stage lung cancer patients whose disease progressed after treatment with Tagrisso. Nearly all patients receiving Tagrisso experience disease progression. According to AstraZeneca’s data, the median time to progression is about 18 months.

DEMONSTRATED CLINICAL ACHIEVEMENT. REQORSA has been tested in more than 50 patients over two Phase 1 clinical trials and a portion of a Phase 2 clinical trial showing a favorable safety profile and evidence of efficacy in lung cancer.

INITIATIATING TWO CLINICAL TRIALS IN LUNG CANCER IN 2021. We plan to initiate a clinical trial of REQORSA combined with Tagrisso and a clinical trial of REQORSA combined with Keytruda in late-stage lung cancer patients in 2021.

WORLD CLASS ACADEMIC PARTNERS. Our cancer therapies were invented and developed at The University of Texas MD Anderson Cancer Center. Our diabetes therapy was invented and developed at the University of Pittsburgh.

EXPANDING OUR PIPELINE. We are constantly working to add to our pipeline of new drugs, drug combinations and disease indications through a robust preclinical research program at MD Anderson, and by actively exploring in-licensing and other acquisition opportunities.

STRONG BALANCE SHEET. With a strong balance sheet, we are well positioned to advance our programs.

-----

No. 1 Potential GNPX Driver Indicator

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.

Read the full article here.

-----

No. 2 Potential GNPX Driver Indicator

Genprex to Receive Inaugural "License of the Year" Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that the Company has been selected to receive the inaugural "License of the Year" award from the University of Pittsburgh Innovation Institute (UPII) in recognition of the advances made with its license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes.

In February 2020, Genprex signed an exclusive license agreement with the University of Pittsburgh for an innovative gene therapy technology developed by lead researcher, George Gittes, M.D. at the Rangos Research Center at the University of Pittsbugh Medical Center ("UPMC") Children’s Hospital. The diabetes gene therapy candidate, GPX-002, which is being evaluated in preclinical studies, reprograms alpha cells in the pancreas into functional beta-like cells, thereby replenishing levels of insulin and providing the potential to cure the disease. The novel infusion is by means of an endoscopic procedure that delivers Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

"We thank the UPII for acknowledging the breakthrough work of Dr. George Gittes and his team at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, whose efforts have produced this highly innovative therapeutic approach to treating diabetes that could replace the need for insulin replacement therapy and ultimately lead to a cure of this devastating illness afflicting tens of millions of people around the world," said Rodney Varner, President and Chief Executive Officer of Genprex. "We are honored to receive this recognition, considering the great number of cutting-edge technologies coming out of this distinguished university and research center. We thank UPII for bestowing this honor on our gene therapy license with Dr. Gittes and the Rangos Research Center and applaud them for the groundbreaking gene therapy research being conducted at this esteemed institution."

Read the full article here.

-----

No. 3 Potential GNPX Driver Indicator

According to MarketBeat, in January of 2021, National Securities initiated coverage on GNPX.

At the same time, they tagged this profile with a $7.00 price target and a "BUY" rating.

From Monday's close of $3.79, this target give GNPX upside potential of approximately 84%.

Now, that's not to say that GNPX is going to go soaring to $7.00 today, but I want you to be aware of the potential upside this firm has provide on this past champ.

-----

No. 4 Potential GNPX Driver Indicator

According to Yahoo Finance, GNPX currently has an approximate 33.71Mn shares in its float.

As we've seen in previous stock profiles, including this one when I brought it to you back in February 2020 (approximately 336% surge in roughly two weeks) and July 2020 (approximately 30% in 2 days), a low float can lead to explosive vertical surges in the short-term due to possible volatility.

Biotech stocks can be very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.

Could the next big news coming from the GNPX camp be the spark to vertical run?

-----

More About The Company: Genprex, Inc.

From the company website:

Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and diabetes.

The company’s lead product candidate, REQORSA™ immunogene therapy (quaratusugene ozeplasmid), is being developed for non-small cell lung cancer (NSCLC). The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. REQORSA uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.

Company Website

-----

Top GNPX Potential Driver Indicators Recap

#1. Positive Preclinical Data News

#2. "License Of The Year" Award From The University Of Pittsburgh Innovation Institute

#3. Analyst Coverage/Price Target

#4. Low Float/Possible Volatility

-----

If there are any updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. A member of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN). From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 4/29/21 and ending on 4/30/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). To date, we have now been compensated four hundred and twenty-three thousand USD via bank wire transfer to disseminate information about (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 4/26/21 and ending on 4/27/21 to publicly disseminate information about (XXII) via Website, Email and SMS. StockNewsWire LLC was paid ninety-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (XXII). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 1/21/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 2/11/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid forty-six thousand USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 5/5/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 6/4/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twelve thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 7/22/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 10/29/20 and ending on 10/30/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 12/22/20 and ending on 12/23/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 5/4/21 and ending on 5/5/21 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (GNPX). To date, we have now been compensated a total of two hundred eighty-six thousand USD to disseminate information about (GNPX). This ninety-five thousand USD has been used for past marketing and advertising and will be used for future marketing and advertising on companies listed above and new companies on an ongoing basis. All companies will be disclosed.